| Document and Entity Information - shares | 3 Months Ended | |
| Mar. 31, 2018 | May 08, 2018 | |
| Document and Entity Information [Abstract] | ||
| Entity Registrant Name | Nautilus Holdco, Inc. | |
| Entity Central Index Key | 1,732,004 | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2018 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Current Reporting Status | Yes | |
| Entity Filer Category | Accelerated Filer | |
| Entity Common Stock, Shares Outstanding | 100 | |
| Document Fiscal Year Focus | 2,018 | |
| Document Fiscal Period Focus | Q1 |
| CONSOLIDATED BALANCE SHEETS | Mar. 31, 2018USD ($) |
| Stockholders' Equity: | |
| Common stock | $ 1 |
| Stockholder receivable | $ (1) |
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS | 3 Months Ended |
| Mar. 31, 2018shares | |
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE OPERATIONS | |
| Weighted average shares outstanding | 96 |
| Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies | 3 Months Ended |
| Mar. 31, 2018 | |
| Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies | |
| 10101 - Disclosure - Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies | NAUTILUS HOLDCO, INC. For the Quarterly Period Ended March 31, 2018 (Unaudited) Note 1 – Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies Nautilus Holdco, Inc., a Delaware corporation (the “Company”), was formed, along with its wholly owned subsidiaries, Island Merger Sub, Inc., a Delaware corporation (“Merger Sub A”) and Boat Merger Sub, Inc., a Delaware corporation (“Merger Sub B”), on January 16, 2018, for the purpose of facilitating the business combination of BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”), and Idera Pharmaceuticals, Inc., a Delaware corporation (“Idera”). In this Form 10-Q we are reporting the shell company results for the Company, Merger Sub A and Merger Sub B for the period from January 16, 2018, the Company’s date of incorporation, to March 31, 2018. As of March 31, 2018, the Company was a wholly owned subsidiary of BioCryst, and Merger Sub A and Merger Sub B, each also a shell company, were wholly owned subsidiaries of the Company. Prior to March 31, 2018, and during the period reported herein, the Company did not conduct any activities other than those incidental to the formation of it and Merger Sub A and Merger Sub B and matters contemplated by the Merger Agreement (as defined below). Pursuant to the terms of a definitive Agreement and Plan of Merger, dated as of January 21, 2018 (the “Merger Agreement”), by and among the Company, BioCryst, Idera, Merger Sub A and Merger Sub B, (i) Merger Sub A will merge with and into Idera (the “Idera Merger”), with Idera continuing as the surviving company and as a wholly owned subsidiary of the Company, and (A) each issued and outstanding share of common stock, par value $0.001 per share, of Idera (the “Idera Common Stock”) (other than the shares that are owned by BioCryst, Idera, the Company, Merger Sub A or Merger Sub B or any wholly owned subsidiary of BioCryst, Idera, Merger Sub A or Merger Sub B) will be converted into the right to receive 0.20 shares of common stock, par value $0.01 per share, of the Company (“Company Common Stock”) and (B) each issued and outstanding share of series A convertible preferred stock, par value $0.01 per share, of Idera (the “Idera Preferred Stock” and, together with the Idera Common Stock, the “Idera Stock”) (other than the shares that are owned by BioCryst, Idera, the Company, Merger Sub A or Merger Sub B or any wholly owned subsidiary of BioCryst, Idera, Merger Sub A or Merger Sub B), will be converted into the right to receive an amount of Company Common Stock based on their liquidation preference, and (ii) Merger Sub B will merge with and into BioCryst (the “BioCryst Merger” and, together with the Idera Merger, the “Mergers”) with BioCryst continuing as the surviving company and as a wholly owned subsidiary of the Company, and each outstanding share of common stock, par value $0.01 per share, of BioCryst (the “BioCryst Stock”) (other than the shares that are owned by BioCryst, Idera, the Company, Merger Sub A or Merger Sub B or any wholly owned subsidiary of BioCryst, Idera, Merger Sub A or Merger Sub B), will be converted into the right to receive 0.50 shares of Company Common Stock. No fractional shares of Company Common Stock will be issued in the Mergers, and stockholders will receive cash in lieu of fractional shares as contemplated by the Merger Agreement. As of the date of this report, and as of March 31, 2018, the Company does not beneficially own any shares of Idera Stock or BioCryst Stock. Following the Mergers, the Company will be the holding company of the combined businesses of Idera and BioCryst. For further information regarding the parties to the Mergers, refer to the section entitled “Note 2 - The Merger Parties”. Basis of presentation . The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Merger Sub A and Merger Sub B. Both subsidiaries were formed to facilitate the Mergers. All intercompany transactions and balances have been eliminated. The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management’s opinion, necessary to present fairly, in all material respects, the consolidated financial position, results of operations, and cash flows of the Company and its subsidiaries, operating as a shell company, for the periods presented and are not indicative of the results that may be expected for a full year. |
| The Merger Parties | 3 Months Ended |
| Mar. 31, 2018 | |
| The Merger Parties | |
| The Merger Parties | Note 2 – The Merger Parties Company The Company was incorporated on January 16, 2018 for the purpose of facilitating the business combination of Idera and BioCryst. The principal executive offices of Idera and BioCryst are located in Cambridge, Massachusetts, and Durham, North Carolina, respectively. Idera Idera is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. Idera uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: its Toll-like receptor, or TLR, targeting technology and its nucleic acid chemistry technology (formerly referred to as Idera’s third generation antisenses, or 3GA technology). Idera developed these platforms based on its scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using its TLR targeting technology, Idera designs synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. Using its nucleic acid chemistry technology, Idera is developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera believes that its nucleic acid chemistry technology may potentially reduce the immunotoxicity and increase the potency of earlier generation antisense and RNA interference, or RNAi, technologies. BioCryst BioCryst is a biotechnology company that designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst focuses on the treatment of rare diseases in which significant unmet medical needs exist and align with BioCryst’s capabilities and expertise. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. Structure-guided drug design is a drug discovery approach by which BioCryst designs synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. BioCryst uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many vital biological reactions. BioCryst’s goal generally is to design a compound that will fit in the active site of an enzyme and thereby prevent its catalytic activity. Merger Sub A Merger Sub A is a Delaware corporation and wholly owned subsidiary of the Company formed for the sole purpose of effecting the Idera Merger. Merger Sub B Merger Sub B is a Delaware corporation and wholly owned subsidiary of the Company formed for the sole purpose of effecting the BioCryst Merger. |
| Shareholder Equity | 3 Months Ended |
| Mar. 31, 2018 | |
| Shareholder Equity | |
| Shareholder Equity | Note 3 – Shareholder Equity As of March 31, 2018, the Company’s authorized share capital consisted of 200,000,000 shares of common stock, par value of $0.01 per share. As of March 31, 2018, outstanding common shares consisted of 100 shares issued to BioCryst, the sole stockholder of the Company. |
| Related Party Transactions | 3 Months Ended |
| Mar. 31, 2018 | |
| Related Party Transactions | |
| Related Party Transactions | Note 4 – Related Party Transactions As of March 31, 2018, a stock subscription receivable of $1.00 was due from BioCryst. |
| Contingencies | 3 Months Ended |
| Mar. 31, 2018 | |
| Contingencies | |
| Contingencies | Note 5 – Contingencies The Company has been involved in certain legal proceedings as set forth under the caption “Litigation Related to the Mergers” in the Registration Statement on Form S-4 (File No. 333-223255), as amended (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission (the “SEC”) by the Company and declared effective on March 29, 2018. In addition, on March 22, 2018, plaintiff Ricky Cohen filed a lawsuit captioned Cohen v. Idera Pharmaceuticals, Inc., et al. , No. 1:18-cv-00428-LPS, against Idera and members of the Idera board in United States District Court for the District of Delaware, alleging violations of Sections 14(a) and 20(a) of the Exchange Act, and SEC Rule 14a-9, for alleged material misstatements or omissions in connection with the proposed transaction. The Cohen complaint includes a demand for, among other things, an injunction preventing defendants from closing the proposed transaction absent certain disclosures of information identified in the complaint. |
| Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies (Policies) | 3 Months Ended |
| Mar. 31, 2018 | |
| Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies | |
| Basis of Presentation | Basis of presentation . The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Merger Sub A and Merger Sub B. Both subsidiaries were formed to facilitate the Mergers. All intercompany transactions and balances have been eliminated. The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Such financial statements reflect all adjustments that are, in management’s opinion, necessary to present fairly, in all material respects, the consolidated financial position, results of operations, and cash flows of the Company and its subsidiaries, operating as a shell company, for the periods presented and are not indicative of the results that may be expected for a full year. |
| Description of Organization and Business Operations (Details) - $ / shares | Jan. 21, 2018 | Mar. 31, 2018 |
| Description of Organization and Business Operations | ||
| Common stock, par value (in dollars per share) | $ 0.01 | |
| BioCryst | ||
| Description of Organization and Business Operations | ||
| Common stock, par value (in dollars per share) | $ 0.01 | |
| Conversion of Stock, Shares Converted | 0.50 | |
| Idera | ||
| Description of Organization and Business Operations | ||
| Common stock, par value (in dollars per share) | $ 0.001 | |
| Converted common stock, par value (in dollars per share) | 0.01 | |
| Series A Preferred Stock | Idera | ||
| Description of Organization and Business Operations | ||
| Preferred stock, par value (in dollars per share) | $ 0.01 | |
| Common Stock | Idera | ||
| Description of Organization and Business Operations | ||
| Conversion of Stock, Shares Converted | 0.20 |
| The Merger Parties (Details) | Mar. 31, 2018item |
| The Merger Parties | |
| Number of distinct proprietary drug discovery technology platforms | 2 |
| Stockholders' Equity (Details) | Mar. 31, 2018$ / sharesshares |
| Shareholder Equity | |
| Common stock, shares authorized (in shares) | 200,000,000 |
| Common stock, par value (in dollars per share) | $ / shares | $ 0.01 |
| Common stock, shares outstanding (in shares) | 100 |
| Related Party Transactions (Details) | Mar. 31, 2018USD ($) |
| Related Party Transaction [Line Items] | |
| Stockholder receivable | $ (1) |
| BioCryst | |
| Related Party Transaction [Line Items] | |
| Stockholder receivable | $ (1) |
